Last reviewed · How we verify
Dexamethasone Late
Dexamethasone is a synthetic glucocorticoid that suppresses inflammation and immune responses by binding to glucocorticoid receptors.
Dexamethasone is a synthetic glucocorticoid that suppresses inflammation and immune responses by binding to glucocorticoid receptors. Used for Prevention or treatment of chronic lung disease (bronchopulmonary dysplasia) in premature neonates requiring mechanical ventilation.
At a glance
| Generic name | Dexamethasone Late |
|---|---|
| Sponsor | NICHD Neonatal Research Network |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Neonatology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone exerts its anti-inflammatory effects by translocating to the nucleus and modulating gene expression of pro-inflammatory cytokines, adhesion molecules, and other immune mediators. In the context of late administration in neonates, it is used to reduce chronic lung inflammation and improve respiratory outcomes in infants at risk of bronchopulmonary dysplasia. The drug's immunosuppressive properties help mitigate ventilator-induced lung injury and inflammatory cascades in premature infants.
Approved indications
- Prevention or treatment of chronic lung disease (bronchopulmonary dysplasia) in premature neonates requiring mechanical ventilation
Common side effects
- Hyperglycemia
- Hypertension
- Increased infection risk
- Gastric perforation
- Growth suppression
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (PHASE2)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL (PHASE1)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Late CI brief — competitive landscape report
- Dexamethasone Late updates RSS · CI watch RSS
- NICHD Neonatal Research Network portfolio CI